AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
Read More
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
Read MoreResults show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
Read MoreNSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment
Read MoreThe new centre will be home to nearly 2,000 world-class researchers and scientists
Read MoreOct 9, 2026 | Healthcare, News
More than 3.5 million people in the UK live with a rare condition
Read MoreThe annual awards recognise excellence across 15 categories spanning innovation, manufacturing, sustainability and leadership
Read MoreThe results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity
Read MoreOct 8, 2026 | Healthcare, News
An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease
Read MoreThis builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
Read MoreThe deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities
Read MoreOct 5, 2026 | Healthcare, News
The new global awareness initiative calls for greater recognition, understanding and support for people living with chronic hand eczema
Read MoreOct 2, 2026 | News
Up to 91% of patients achieved at least 75% improvement in eczema severity and up to 67% achieved near-complete skin clearance
Read More
